New Revolutionary Treatment for Glaucoma: iDose® TR is Now Available at Harvard Eye Associates

Harvard Eye Associates, located in Laguna Hills, California, announces the introduction of iDose® TR, a therapeutic breakthrough for patients suffering from high eye pressure glaucoma. FDA-approved, iDose® TR continuously delivers treatment directly inside the eye for better disease management.

Offering hope to patients, this method provides an alternative to traditional eye drops, which are often improperly administered and can cause unpleasant side effects. Dr. Savak Teymoorian, a specialist in glaucoma and cataract surgery, performed the first treatments at the Alicia Surgery Center, marking a significant milestone in the fight against eye diseases.

The iDose® TR device from Glaukos has shown in clinical studies that 80% of treated patients no longer required daily medication after 12 months. This innovation is particularly relevant for patients who struggle to adhere to their daily medication regimen or whose condition cannot be adequately controlled with topical medications.